This study highlights MPO and FCGR1A as particularly compelling biomarkers for both advanced adenoma detection and early CRC monitoring, addressing key clinical unmet needs in CRC diagnosis and prognosis. This evidence concerns the gene FCGR1A and colorectal carcinoma.